Clalit researchers and their colleagues from Harvard University in Boston analyzed data from 182,122 Clalit members, all 60 years of age or older, who received the fourth dose of Pfizer.
The control group consisted of the same number of people in the same age group, who had received the third dose at least four months earlier and had not received the fourth dose.
The study evaluated the effectiveness of a fourth dose between January 3 and February 18, when the Omicron variant was predominant in Israel.
Research has also shown that the effects of the fourth dose can last for more than 30 days without significant reduction.
“The study unequivocally demonstrates that the fourth dose provides effective protection in preventing disease,” said Ran Balicer, director of the Clalit Research Institute.
He added: “It will help people make decisions about a fourth vaccine based on their individual level of risk.
Source: IANS
